

Natalie S Callander

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5733869/publications.pdf>

Version: 2024-02-01

32
papers

2,680
citations

566801

15
h-index

454577

30
g-index

32
all docs

32
docs citations

32
times ranked

2985
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. <i>Leukemia</i> , 2022, 36, 877-880.	3.3	18
2	Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2901-2912.	0.8	124
3	ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 284-293.	0.6	11
4	A Hyaluronan and Proteoglycan Link Protein 1 Matrikine: Role of Matrix Metalloproteinase 2 in Multiple Myeloma NF- κ B Activation and Drug Resistance. <i>Molecular Cancer Research</i> , 2022, 20, 1456-1466.	1.5	5
5	A biobehavioral intervention to enhance recovery following hematopoietic cell transplantation: Protocol for a feasibility and acceptability randomized control trial. <i>Contemporary Clinical Trials Communications</i> , 2022, 28, 100938.	0.5	1
6	Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapy. <i>American Journal of Hematology</i> , 2022, 97, 1170-1177.	2.0	3
7	Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	16
8	Flat-dose granulocyte colony-stimulating factor evaluation after autologous hematopoietic stem cell transplant in multiple myeloma patients: Does one dose fit all?. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1716-1722.	0.5	0
9	Expression of <i>Nras</i> <i>Q61R</i> and <i>MYC</i> transgene in germinal center B cells induces a highly malignant multiple myeloma in mice. <i>Blood</i> , 2021, 137, 61-74.	0.6	21
10	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. <i>Leukemia</i> , 2021, 35, 18-30.	3.3	69
11	The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance. <i>American Journal of Hematology</i> , 2021, 96, 846-853.	2.0	16
12	Progress in the Management of Smoldering Multiple Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 172-182.	1.2	3
13	Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). <i>Blood Cancer Journal</i> , 2021, 11, 103.	2.8	32
14	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 207-221.	5.1	544
15	Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. <i>Ophthalmology and Therapy</i> , 2020, 9, 889-911.	1.0	101
16	Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 26-27.	0.6	6
17	Granulocyte colony-stimulating factor utilization postautologous hematopoietic stem cell transplant in multiple myeloma patients: Does one size fit all?. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1135-1141.	0.5	1
18	Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , the, 2019, 6, e459-e469.	2.2	174

#	ARTICLE	IF	CITATIONS
19	Bone Marrow Stromal Cells Transcriptionally Repress ESR1 but Cannot Overcome Constitutive ESR1 Mutant Activity. <i>Endocrinology</i> , 2019, 160, 2427-2440.	1.4	4
20	Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. <i>Leukemia</i> , 2019, 33, 2266-2275.	3.3	385
21	Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2558-2562.	0.6	13
22	Reduction in oral mucositis severity using a topical vasoconstrictor: A case report of three bone marrow transplant patients. <i>Integrative Cancer Science and Therapeutics</i> , 2018, 5, .	0.1	1
23	Versican-Derived Matrikines Regulate Batf3â€“Dendritic Cell Differentiation and Promote T Cell Infiltration in Colorectal Cancer. <i>Journal of Immunology</i> , 2017, 199, 1933-1941.	0.4	82
24	Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. <i>Lancet, The</i> , 2016, 387, 1551-1560.	6.3	724
25	Single-molecule analysis reveals widespread structural variation in multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 7689-7694.	3.3	43
26	Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma. <i>Cancer Immunology Research</i> , 2015, 3, 881-890.	1.6	24
27	Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 875-882.	1.1	31
28	SWOG 1211: Initial Report on PHASE I Trial of RVD-Elotuzumab for NEWLY Diagnosed High Risk Multiple Myeloma (HRMM). <i>Blood</i> , 2014, 124, 4762-4762.	0.6	4
29	The Veterans Health Administration Provides Equal Access to Autologous Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. <i>Blood</i> , 2014, 124, 2629-2629.	0.6	0
30	Microscale functional cytomics for studying hematologic cancers. <i>Blood</i> , 2012, 119, e76-e85.	0.6	41
31	VcRâ€“CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. <i>British Journal of Haematology</i> , 2011, 155, 190-197.	1.2	48
32	Bortezomib-Resistant Nuclear Factor-Î²B Activity in Multiple Myeloma Cells. <i>Molecular Cancer Research</i> , 2008, 6, 1356-1364.	1.5	135